www.bloomberg.com
Open in
urlscan Pro
104.108.39.139
Public Scan
Submitted URL: https://info.silobreaker.com/e2t/tc/VWT43p8WpcPLVD1nwC4sCB-_W4bWRWk4jjjDkN35KTC_2-HwLV1-WJV7CgYwxW3_ffwz1fd7RFN4Nnd2z1PxkhVrS...
Effective URL: https://www.bloomberg.com/news/articles/2020-11-11/brazil-clears-sinovac-trial-to-resume-two-days-after-halting-it?_hsmi=8...
Submission: On November 12 via api from DE
Effective URL: https://www.bloomberg.com/news/articles/2020-11-11/brazil-clears-sinovac-trial-to-resume-two-days-after-halting-it?_hsmi=8...
Submission: On November 12 via api from DE
Form analysis
1 forms found in the DOMGET https://tr.snapchat.com/cm/i
<form method="GET" action="https://tr.snapchat.com/cm/i" target="snap04796034807823881" accept-charset="utf-8" style="display: none;"><iframe id="snap04796034807823881" name="snap04796034807823881"></iframe><input name="pid"></form>
Text Content
Skip to content Skip to content Bloomberg the Company & Its ProductsThe Company & its ProductsBloomberg Terminal Demo RequestBloomberg Anywhere Remote LoginBloomberg Anywhere LoginBloomberg Customer SupportCustomer Support MenuSearch Bloomberg Sign InSign OutSubscribe * HOME * MARKETS * TECHNOLOGY * POLITICS * WEALTH * PURSUITS * OPINION * BUSINESSWEEK * NEW ECONOMY * GREEN * CITYLAB -------------------------------------------------------------------------------- * QUICKTAKE * BLOOMBERG TV+ * PODCASTS * RADIO -------------------------------------------------------------------------------- * NEWSLETTERS * WATCHLIST * SUBSCRIBE * SIGN IN -------------------------------------------------------------------------------- * SUBMIT A TIP * HELP CENTER * LICENSE Read * Bloomberg New Economy * Future Finance * Wealth * Next China * Crypto * Checkout * Hyperdrive * Well Spent * Prognosis * Equality * Good Business * Billionaires * Graphics * Sponsored Content * Screentime * Retirement Center Watch * The David Rubenstein Show * Art + Technology * Inspire GO Special Reports * Where to Invest $10,000 * 50 Companies to Watch in 2018 * Where to Invest $1 Million Follow * Facebook * Twitter * Instagram * LinkedIn Read * Economics * Deals * The FIX | Fixed Income * ETFs * FX * Factor Investing * Markets Magazine Watch * Daybreak * Surveillance * Markets * What'd You Miss * Real Yield * Charting Futures * Futures in Focus Follow * Twitter * Facebook Data * Stocks * Currencies * Commodities * Rates & Bonds * Sectors * Economic Calendar Listen * What Goes Up * Stephanomics * Odd Lots * Surveillance * P&L * Trillions Read * Work Shifting * Code Wars * Startups * AI * Mobile * Big Data * Cloud Computing * U.S. * Global Special Reports * The Elon Musk Tracker * Tesla Model 3 Tracker Watch * Bloomberg Technology TV * Studio 1.0 Listen * Decrypted Follow * Twitter * Facebook Read * Election 2020 * Trump Tracker * Global Trade Tracker Listen * Sound On * Bloomberg Law Watch * Balance of Power Subscribe * Balance of Power Follow * Twitter * Facebook Read * Investing * Living * Opinion & Advice * Savings & Retirement * Taxes * Reinvention Watch * Good Money Listen * The Paycheck Follow * Twitter * Facebook * Instagram Read * Travel * Autos * Homes * Living * Culture * Style Special Reports * Property Listings * London Property Prices * New York Property Prices * How to Spend Your Bonus Watch * Made * Traveler * Invitation Only Follow * Twitter * Facebook * Instagram Read * Editorials Follow * Twitter * Facebook * Instagram Listen * Masters in Business Subscribe * Bloomberg Opinion Today * Money Stuff * Ritholtz's Reads * Early Returns * Sparklines Special Reports * Sooner Than You Think * Business of Equality * The Year Ahead: 2020 * The Bloomberg 50 * Best B-Schools Watch * Hello World The Magazine * Subscribe Follow * Twitter * Facebook * Instagram Watch * New Economy Conversation Series Listen * Stephanomics Subscribe * Turning Points Follow * Twitter * Facebook * New Economy Forum Read * Science & Energy * Climate Adaptation * Finance * Politics * Culture & Design Special Reports * Data Dash Subscribe * Daily newsletter Follow * Twitter * Facebook * Instagram Read * Design * Culture * Transportation * Economy * Environment * Housing * Justice * Government Subscribe * Daily newsletter Follow * Twitter * Facebook * Instagram * LinkedIn Live * Watch Now Original Series * Storylines * Moonshot * Hello World * Good Money * Game Changers * CityLab Solutions * Accelerate * See all series... Follow * YouTube * Twitter * Instagram * Facebook Watch Live TV * US * Europe * Asia * Australia * Schedule+Shows Shows * Surveillance * Daybreak * Markets * Balance of Power * What'd You Miss? * Bloomberg Technology * All Shows... Follow * YouTube * Twitter * Facebook Listen * What Goes Up * Stephanomics * Odd Lots * Decrypted * Masters in Business * Surveillance * P&L * Businessweek * The Pay Check * Prognosis * Travel Genius * Works for Me * Trillions * All Podcasts… * All Radio Shows… Photographer: Jonne Roriz/Bloomberg prognosis CHINA’S CORONAVAC TRIAL RESUMES IN BRAZIL AFTER ‘ADVERSE EVENT’ By Simone Preissler Iglesias and Julia Leite November 11, 2020, 3:40 PM GMT+1 Updated on November 12, 2020, 2:44 AM GMT+1 3:03 CHINA’S CORONAVAC TRIAL RESUMES IN BRAZIL AFTER ‘ADVERSE EVENT’ By Simone Preissler Iglesias and Julia Leite , November 11, 2020, 3:40 PM GMT+1 * Reversal comes amid criticism that the halt was politicized * Sinovac vaccine has been at center of political feud in Brazil LISTEN TO ARTICLE 3:03 SHARE THIS ARTICLE Share Tweet Post Email Photographer: Jonne Roriz/Bloomberg Photographer: Jonne Roriz/Bloomberg Brazil reversed its decision to suspend trials of a coronavirus vaccine from Chinese developer Sinovac Biotech Ltd., allowing tests to resume less than 48 hours after being halted amid criticism the initial pause was politically motivated. In a statement posted on its website Wednesday, health agency Anvisa said it initially got “precarious data” on a “grave” event, which led it to suspend the study late Monday. The agency added that it reversed its previous ruling after receiving new information, and that it will keep monitoring the case. Read More: Brazil’s Halting of China Vaccine Baffles Local Researchers On Tuesday, Sao Paulo’s Instituto Butantan, which partnered with Sinovac to produce the vaccine locally, criticized the suspension, saying it was not warned of the move and that the reported death of a volunteer was not related to the shot. More from When Will Covid Be Defeated? You’ll Need Patience: Coronavirus Q&A Turkey Bans Public Smoking to Enforce Wearing Masks Europe Hot Spots Easing; Global Deaths Hit Record: Virus Update Moderna Poised to Take Vaccine Spotlight With Data Due Sinovac’s vaccine has become the focus of an escalating feud in Brazil. President Jair Bolsonaro stepped up criticism of CoronaVac last month, saying China lacks credibility to come up with solutions for the coronavirus crisis and that people wouldn’t feel safe with the shot “due to its origin.” Chinese vaccine developers have been compelled to find countries where the coronavirus is still spreading to host their final-stage trials, since the Asian nation’s domestic outbreak has been largely contained. Geopolitical tensions have affected the development process due to growing hostility toward Beijing from some countries over a range of issues like trade and the pandemic’s origins. After the trial was paused, Bolsonaro on his Facebook account responded to a supporter and appeared to celebrate the decision, writing, “another win for Bolsonaro.” He has not commented on the resumption of the trial. The Butantan researchers have suggested the participant could have died in a traffic accident, while Anvisa said earlier it had no information about the potential cause of death being suicide as reported by local media. China’s Race for Covid-19 Vaccine Raises Safety Questions “The decision to interrupt without having all the details seems premature,” said Juarez Cunha, head of the Brazilian Immunization Society. “Given Butantan’s credibility, I am sure if there was any suspicion of a related grave adverse event, the researchers themselves would have called attention to it and suggested the suspension.” Sinovac said in a statement on its website earlier this week that it’s confident in the safety of its vaccine. Halts to investigate serious adverse events are not uncommon in large-scale drug trials and two western developers -- AstraZeneca Plc and Johnson & Johnson -- paused their vaccine trials in recent months due to such incidents, only to re-start them after investigation. Chinese vaccine developers have been at the forefront of the global race to create an effective immunization against the virus. The push has taken on vital importance as countries look to move beyond Covid-19 and more definitively re-open their economies. Unlike American pharmaceutical firm Pfizer Inc., which this week revealed “extraordinary” positive preliminary data from final-stage trials of its candidate developed with BioNTech, no Chinese developer has yet publicized data on the efficacy of their shots. — With assistance by Andre Romani Pinto Published on November 11, 2020, 3:40 PM GMT+1 Updated on November 12, 2020, 2:44 AM GMT+1 Have a confidential tip for our reporters? GET IN TOUCH Before it's here, it's on the Bloomberg Terminal. LEARN MORE LISTEN TO ARTICLE 3:03 SHARE THIS ARTICLE Share Tweet Post Email by Taboolaby Taboola Sponsored LinksSponsored Links Promoted LinksPromoted Links From The Web Worldemand Erinnerst du dich an Kandi von 'Two and a Half Men'? So sieht sie jetzt ausWorldemand Hören Heute Arzt verrät: das Geheimnis der neuen Mini-HörgeräteHören Heute Pilz Research Ärzte verblüfft: Ein einfacher Tipp gegen Nagelpilze (Heute Abend testen)Pilz Research Do It Houses Als die Gäste ihr Hochzeitskleid sahen, dachten sie, es sei ein WitzDo It Houses Travel Den 20 Seriously Deadly Places You Should Never Ever SwimTravel Den Tinnitus Research Ärzte verblüfft: Ein einfacher Tipp lindert jahrelangen Tinnitus (Heute Abend testen)Tinnitus Research LIVE ON BLOOMBERG Watch Live TV Listen to Live Radio Video Player is loading. Play Video Pause Unmute Current Time 0:45 / Duration -:-:- Loaded: 0% 0:00:45 Progress: 0% Stream Type LIVE Remaining Time --:-:- Playback Rate 1x Chapters * Chapters Captions * captions settings, opens captions settings dialog * captions off, selected Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque Font Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps Reset restore all settings to the default valuesDone Close Modal Dialog End of dialog window. Play Again MOST READ 1. business Covid Superspreader Risk Is Linked to Restaurants, Gyms, Hotels 2. business Deep-Freeze Hurdle Makes Pfizer’s Vaccine One for the Rich 3. business China and 14 Asian Nations to Sign World's Biggest Free-Trade Deal 4. technology Singapore to Introduce New Visa to Draw Top Global Tech Talent 5. business California Infections Rise; N.Y. Restaurant Curfew: Virus Update Terms of Service Do Not Sell My Info (California) Trademarks Privacy Policy ©2020 Bloomberg L.P. All Rights Reserved Careers Made in NYC Advertise Ad Choices Contact Us Help Your free limit of content is about to expire. Your monthly limit of free content is about to expire. Stay on top of historic market volatility. Try 3 months for $105 $6. Cancel anytime. Claim This Offer Sign in Bloomberg Anywhere clients get free access Your free limit of content is about to expire. Your monthly limit of free content is about to expire. Stay on top of historic market volatility. Try 3 months for $105 $6. Cancel anytime. Claim This Offer Sign in Bloomberg Anywhere clients get free access Your free limit of content is about to expire. Your monthly limit of free content is about to expire. Stay on top of historic market volatility. Try 3 months for $105 $6. Cancel anytime. Claim This Offer